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1 ABBREVIATIONS 
 
CNS - central nervous system 
BZD - benzodiazepines 
VA - valerenic acid 
GABA - gamma amino butyric acid 
ESCOP - The European Scientific Cooperative On 
 Phytotherapy 
USP - US Pharmacopoeia 
Eur. Ph. - European Pharmacopoeia 
i.p. - intraperitoneal 
p.o. - peroral 
EPM - elevated plus maze 
MBT - marble burying test 
DSM IV TR - The Diagnostic and Statistical Manual of   
  Mental Disorders Text Revision 
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2 ABSTRACT 
 
Anxiety affects many people world-wide and has become an 
important area of research interest in psychopharmacology 
during this decade. Benzodiazepines are the major class of 
compounds used in anxiety and they have remained the most 
commonly prescribed treatment for anxiety. However, the 
realization that benzodiazepines present a narrow safety margin 
between the anxiolytic effect and causing unwanted side effects 
has prompted many researchers to develop new compounds in 
the hope to find anxiolytic drugs that have less undesirable 
effects. It has been shown recently that extracts prepared from 
the roots of Valeriana officinalis L. exerted anxiolytic activity in 
animal models. However, the compounds responsible for this 
effect are still unknown. It is therefore the goal of the present 
study to test selected isolated compounds (valerenic acid, 
apigenin, linarin) from Valeriana in order to get information 
about possible anxiolytic active compounds using the elevated 
plus maze (EPM) in mice. Mice have been orally treated with 
these isolated compounds in different concentrations and the 
anxiolytic behavior was evaluated in the EPM. Valerenic acid 
showed significant anxiolytic effects at the concentration of 0.5 
mg/Kg. A lower dose as well as higher doses did not show an 
anxiolytic effect in comparison to the used control diazepam. 
The flavonoids apigenin and linarin did not show any anxiolytic 
effects in comparison to the control group. 
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3 Zusammenfassung 
Diese Diplomarbeit beschäftigt sich damit, die anxiolytische 
Wirkung von verschiedenen isolierten Inhaltsstoffen aus Valeriana 
officinalis L. (Valerianaceae) zu untersuchen. Allgemeine 
Angstzustände sind heute eine weit verbreitete ernstzunehmende 
Erkrankung welche das Leben der Betroffenen stark 
beeinträchtigen kann. Benzodiazepine werden in diesen Fällen am 
häufigsten verschrieben, jedoch weisen diese Arzneistoffe 
schwerwiegende Nebenwirkungen auf, wie Sedierung oder 
Beeinträchtigung der kognitiven Leistung. Diese Nebenwirkungen 
können das Alltagsleben der Patienten ebenfalls beeinträchtigen, 
daher ist es wichtig Anxiolytika ohne die beschriebenen 
unerwünschten Wirkungen zu finden. 
Baldrian hat sich im traditionellen Gebrauch als wirksames 
Einschlaf- und Beruhigungsmittel etabliert. Es sind auch zahlreiche 
Studien zur einschlaffördernden Wirkung des Baldrians 
durchgeführt worden, jedoch wird die anxiolytische Wirkung noch 
untersucht. Bisher wurden in einigen in vitro Studien 
nachgewiesen, dass die Wirkung von, der im Baldrian enthaltenen 
Valerensäure im Zentralnervensystem über GABAA-Kanäle 
vermittelt wird.  
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Das Ziel der vorliegenden Arbeit war es, die anxiolytische Wirkung 
von Valerensäure und anderen Inhaltsstoffen (Apigenin, Linarin) 
des Baldrians im Tiermodell festzustellen, um Hinweise auf 
moegliche Wirkstoffe zu erhalten. Als Testsystem wurde der 
sogenannte Elevated Plus Maze Test (EPM) in Mäusen verwendet. 
Von den getesteten Substanzen konnte für Valerensäure, in einer 
Konzentration von 0.5 mg/Kg eine anxiolytische Wirkung 
festgestellt werden. Eine niedrigere Konzentration zeigte keine 
Wirkung im Vergleich mit der Kontrollsubstanz Diazepam. Mit 
steigender Konzentration nahm die anxiolytische Wirkung ebenfalls 
ab. Für die Flavonoide Apigenin und Linarin konnte im EPM kein 
anxiolytischer Effekt festgestellt werden. 
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4 Introduction 
 
Anxiety disorders are a group of mental disorders that become 
manifest in different forms and may interfere with activities of daily 
living. Individuals suffering from anxiety disorders (AD) have large 
social and economic implications, such as loss of workplace 
productivity. Treatment of anxiety disorders includes 
psychoanalytic, cognitive and pharmacologic therapies. 
Benzodiazepines are the most prescribed anti-anxiety drugs though 
they can have severe sedative and cognitive side effects. 
Therefore, there is a goal for the pharmaceutical industry to 
develop new anti-anxiety drugs to reduce undesirable sedative and 
amnesic side effects. Many patients suffering from AD also seek 
help outside the realm of psychiatry such as alternative medicine 
providers. There is a growing market for self-administration of 
herbal and other dietary supplements having anxiolytic effects. 
Among anxiolytic herbs kava kava (not used anymore because of 
hepatotoxicity), valerian root, passion flower and others are 
considered. The safe use of plant derived medicines requires a 
detailed understanding of their pharmacologic mechanisms based 
on in vitro and in vivo test results. [A.A. Roberts; Compl alt appr to 
Biomedicine] 
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4.1 Classification of anxiety disorders 
 
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-
TR) includes the following conditions under the heading of anxiety 
disorders: acute stress disorder, post-traumatic stress disorder, 
social phobia and specific phobia. These disorders vary in their 
severity and symptomatology, as well as treatment responses. 
[A.A. Roberts; Compl alt appr to Biomedicine] 
There are five different forms of anxiety disorders which are: 
• panic disorder (PD),  
• obsessive-compulsive disorder (OCD), 
• social anxiety disorder (SAD), 
• post-traumatic stress disorder (PTSD)  
• generalized anxiety disorder (GAD).  
(This thesis main focus is on generalized anxiety disorders.) 
Due to research it is now understood that anxiety disorders are 
mediated by autonomic and neuroendocrine systems that are 
under the control of the central nervous system (CNS). The 
modulation of normal and pathologic anxiety states is associated 
with multiple regions of the brain and abnormal function in several 
neurotransmitter systems, including norepinephrine (NE), gamma-
aminobutyric acid (GABA), serotonin (5-HT), corticotrophin-
releasing factor (CRF) and cholecystokinin. Therefore, the system 
of action of anxiety disorders in the central nervous system has 
been characterized and gives the impulse for research and 
development of anxiolytic drugs. [A.A. Roberts; Compl alt appr to 
Biomedicine], [Pharmacotherapy: A Pathophysiologic Approach, 
Chapter 73…] 
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In the search for benzodiazepine site ligands with higher 
therapeutic selectivity and a reduced side effect profile, GABAA-
receptor subtypes have long been considered to be promising 
targets [H. Möhler et al]. Therefore, pharmaceutical research in 
that area aims to develop selective anxiolytics without a sedative 
component and the major side effects known of benzodiazepines. 
Anxiolytic agents are evaluated by behavioral tests using animals 
that are exposed to environmental stressors in controlled 
laboratory conditions. 
 
4.2 GABAA-Receptors and Anxiety 
The pathophysiologic mechanisms underlying anxiety are not yet 
completely determined. GABA (γ-aminobutyric acid) is a 
neurotransmitter in the central nervous system that has a 
dampening influence on neuronal activity by protecting neurons 
from toxic overstimulation. This neurotransmitter has shown to be 
involved in the system of anxiety disorders. The GABA receptors 
are the point of action for GABA. There are two superfamilies of 
GABA protein receptors: GABAA and GABAB. With regards to 
anxiety disorders the effect of GABA takes place mainly on the type 
A GABA receptors (GABAA) which are widely located throughout the 
CNS. They are also the main targets for several classes of 
anxiolytic and sedative drugs as benzodiazepines (e.g. diazepam), 
barbiturates or alcohol. These drugs potentiate the activity of 
GABAA-receptors by allosteric stimulation of the inhibitory effect of 
GABA on these receptors.  
GABAA receptors are ligand-gated trans-membrane ion channels 
[fig. 1]. They consist of five trans-membrane protein subunits that 
surround a central pore which is a chloride-conducting ion channel.  
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Activation of these receptors leads to an increased chloride influx 
which results in a hyperpolarized membrane and hence neuronal 
inhibition occurs. Subunits are 6α, 3β, 3γ, δ, ε, θ and π. GABAA 
receptors containing α1-3β2/3γ2 in a 2:2:1 stoichiometry represent 
the major GABAA subtype in the mammalian CNS. However, the 
determining factor of the GABA activity is merely the identity of the 
α subunit(s). The benzodiazepines binding site is located at the 
interface of an α and a γ subunit, therefore the identity of both 
subunits have an influence on the activity of BZD site ligands.  
Studies have shown that α2-subunit containing receptors mediate 
an anxiolytic effect. Anxiolytic, sedative and amnesic properties of 
diazepam are mediated by distinct subtypes of GABAA receptors. 
Therefore, drugs have been developed to be subtype-specific in 
order to avoid undesirable effects. The focus of research 
considering new anxiolytic drugs has been put in order to have a 
maximum of anxiolytic activity while reducing undesirable sedative 
and amnesic effects. Studies using genetic engineering techniques 
(e.g. Knock-out, knock-in) have been conducted to determine the 
GABAA receptor complex in the pathophysiology of anxiety. 
Neuroimaging studies in humans with anxiety disorders have 
reported reductions in GABA levels and GABAA-benzodiazepines 
receptor binding sites so there is considerable evidence for a 
connection between GABAA-dysfunction and the pathophysiology of 
anxiety disorders. 
 
 
 
 
Fig. 1: GABAA receptor 
http://www.cnsforum.com/imagebank/section/Receptor_Gabanergic/default.aspx 
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4.3 Drug Therapy of Anxiety Disorders 
 
The desired outcome of the treatment of anxiety disorders is to 
reduce the severity and duration of the anxiety symptoms while 
improving the overall functioning. Therefore, psychotherapy should 
be considered for all patients. Standard therapy consists of a 
combination of psychotherapy and drug therapy. Antianxiety 
medication is indicated in case of functional disability. 
Due to comorbid depressive symptoms, antidepressants such as 
selective-serotonin-reuptake-inhibitors (SSRIs) emerged as the 
treatment of choice and became first-line drugs. However a 
therapy with antidepressants shows an optimal response after 6 to 
8 weeks or longer.  
Second-line drugs and most commonly prescribed drugs are on 
GABAA-receptor interacting benzodiazepines. They provide rapid 
relief in acute situations as an effect is shown to the initial 
treatment after 2 to 4 weeks. Benzodiazepines reduce somatic 
symptoms but they do not have any effects on psychic symptoms 
which can be relieved with antidepressants. All benzodiazepines are 
equally effective anxiolytics but their pharmacokinetic varies. The 
pharmacologic effect of benzodiazepines is based on an allosteric 
binding to the GABAA receptor which leads to conformational 
changes in the GABA binding site, thereby increasing the affinity of 
the receptor for GABA. The frequency of chloride channel openings 
is increased which leads to neuronal hyperpolarization and 
therefore central nervous depression. Long-term use of 
benzodiazepines has shown to lead to dependence, withdrawal 
symptoms and impairment of the memory. Other adverse effects 
which may occur are sedation and drowsiness.  
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Additionally benzodiazepines do also have a high abuse potential. 
Therefore it is necessary to find anxiolytic drugs with less central 
nervous system related side effects.  
Some herbal medicines have shown to possess anxiolytic like 
effects which lead researchers to conduct numerous studies 
approaching this topic. Valerian is one of these plants. A lot of 
studies have been already conducted on Valerian’s sleep enhancing 
but less on its anxiolytic properties.  
 
4.4 Botanical Characterization  
Botanical nomenclature: Valeriana officinalis L., s.l. 
Botanical family: Valerianaceae 
The name Valerian is said to be derived either from Valerius, the 
first who reportedly utilized the plants medicinal properties, or from 
velere, the Latin term for health or well-being. Valerian has been 
used medicinally for at least 2000 years. Dioscorides (ca. AD 40-
80) already wrote about several Valerian species and Galen 
reported sedative effects. One of its first utilization was as a 
treatment for epilepsy in the late 16th century and became 
routinely used for the treatment of various nervous disorders. In 
the late 19th and early 20th century Valerian was considered to be 
sedative and to have an activity as a cerebral stimulant as well as 
having an analgesic effect. It was used as a treatment of hysteria, 
epilepsy and menopausal nervous anxiety. [Amer Herb Pharmac - 
Monograph] 
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Valeriana officinalis is an herbaceous plant that can reach about 
one meter in height and is cultivated in many European countries, 
as well as in Japan and North America. The root, rhizomes and 
stolons are the pharmaceutically used parts of the plant. Valerian 
root is known for its characteristic, usually as unpleasant described 
smell. [Heinrich M et al]  
 
 
Fig. 2: Valeriana officinalis L. 
http://www.botanical.com/botanical/mgmh/v/valeri01-l.jpg 
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Fig. 3 Valeriana officinalis L. 
http://www.botanikus.de/Heilpflanzen/Baldrian/baldrian.html 
 
4.4.1 Constituents 
The roots of Valerian are used for therapeutic purposes. According 
to divers Pharmacopoeia, Valerian roots are defined as dried 
underground parts of Valeriana officinalis L., s.l. including the 
rhizome, the roots and stolons [ESCOP Monographs, USP]. The 
roots contain several compounds some of with demonstrable 
pharmacological activity as [Am Herb Pharmac]  
• essential oils, sesquiterpenes,  
• volatile sesquiterpene carboxylic acids (valerenic acid and 
derivatives)  
• flavonoids: 6-methylapigenin, linarin, hesperidine 
• amino acids: GABA, glutamine and arginine, tyrosine 
• alkaloids 
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and small amounts of:  
phenolic acids, chlorgenic acid, caffeic acid, choline, ß-
sitosterol, fatty acids and various minerals 
[Am. Herb. Pharmac], [Hänsel, Sticher] 
The Pharmacopoeia Europaea (Ph. Eur.) monograph specifies that 
valerian root contains not less than 5 ml/Kg of essential oil for the 
whole drug and not less than 0.17% of sesquiterpenic acids 
expressed as valerenic acid. Everything was calculated with 
reference to the dried drug. [ESCOP]  
 
4.4.2 Indication 
Therapeutic indications for Valeriana radix are for relief of 
temporary mild nervous tension and/or difficulty in falling asleep. 
The drug is used for oral administration e.g. as a tea infusion. One 
of the main advantages of using Valerian root as a sedative is that 
there is no dependence nor withdrawal symptoms reported thus no 
restrictions on the duration of administration. There is also no 
impairment on vigilance which was shown in several studies. No 
hangover effect has been shown eight hours after taking the 
preparation. Neither repeated evening administration for 14 days of 
600 mg of valerian root extract (comply with 3 g of drug) showed 
any impairment of the vigilance the morning after. Furthermore no 
adverse effects have been confirmed, although there were benign 
symptoms observed at an overdose of Valerian root according to 
20 g like fatigue, abdominal cramp, chest tightness, light 
headedness, hand tremor and mydriasis. [ESCOP] 
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4.4.3 Anxiolytic Properties 
Valerenic acid (VA) [fig. 4] has been identified as a β-subunit 
specific GABAA receptor modulator by a study performed at the 
University of Vienna on Xenopus laevis oocytes. It is suggested 
that VA interacts with the binding site of anesthetics such as 
loreclezol or etomidate [S. Khom et al. 2007, G. Trauner et al. 
2008]. Therefore, it is supposed that VA is responsible for 
Valerian’s sedative, sleep-enhancing and anxiolytic properties. 
However, Valerian extracts might contain additional modulators of 
GABAA receptors. Various compounds have been discussed to be 
also responsible for the CNS-depressant effect. It is still uncertain 
what the actual active compound might be. Flavonoids such as 
apigenin [fig. 5] and linarin [fig. 6] did also show sleep-enhancing, 
sedative and anxiolytic-like properties in animal models. Data of a 
study published by G. Trauner et al in 2008 suggests that the 
extent of GABAA receptor modulation by Valerian extracts is related 
to the content of VA. It should be considered that many other 
compounds play an important role in the efficacy of Valeriana 
officinalis L.  
In vitro experiments of various valerian root extracts have shown 
that some interact with GABA chloride channel complex. 
Additionally the extract inhibits the presynaptic re-uptake and 
induces the release of radiolabelled GABA. A receptor binding of 
various constituents on adenosine receptors as well as on serotonin 
receptor subtypes has been observed which might also have an 
influence to increased presynaptic neurotransmitter concetration. 
[Hänsel, Sticher 2010] Valerian extracts interact with GABAA 
receptor complexes on a different site than diazepam. [ESCOP] The 
binding sites of VA and the BZDs like diazepam are independent of 
each other thus studies proved VA to be β-subtype specific where 
as benzodiazepine binding site is supposed to be at the interface 
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between the α and γ subunit. Additive effects have been observed 
when VA was coapplicated with diazepam. [S. Khom et al 2007]. 
Diazepam permeates quickly the blood-brain barrier through 
passive diffusion, therefore an effect can be observed within short 
time. Whereas VA permeates slowly and its transport systems are 
still unclear, an effect can be observed only after two to four weeks 
of therapy. [Hänsel, Sticher 2010] 
In vivo experiments of isolated compounds such as valerenic acid, 
valeranal and valeranone, which were administered by 
intraperitoneal (i.p.) injection, showed a central depressive and/or 
muscle relaxant activity in mice. After i.p. administration of 
valerenic acid to mice of 17 – 25 g body weight 400 mg/Kg caused 
heavy convulsions leading to the death of 6 out of 7 mice within 24 
hours. [Khom S. et al] The mechanism of action and the 
substances responsible for the already mentioned CNS-effects are 
like for many other herbal medicines yet not fully determined. In 
vivo studies need to be conducted to investigate anxiolytic 
properties of isolated Valerian compounds. 
Several studies with natural and synthetic flavones and flavanons 
have shown that they can modulate GABA-induced chloride 
current, either positively or negatively. Linarin is reported to have 
sedative effects therefore it is assumable that it might also have 
anxiolytic properties. 
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Camomille tea has been traditionally used as a relaxing tea. Its 
relaxing properties have been attributed to the flavonoid apigenin, 
which can also be found in Valerina officinalis L. Ethological studies 
testing apigenin have shown an anxiolytic like effect but no 
sedative side effects, although in-vitro studies did not prove any 
anxiolytic properties [Viola H et al 1994]. Apigenin has been shown 
to be a non-competitive antagonist of GABAA-receptors but its 
inhibitory effect could not be blocked by benzodiazepine antagonist 
flumazenil. However, apigenin seems to enhance the actions of 
diazepam which might be therapeutically interesting, given that the 
diazepam dose could be reduced. [Campbell EL et al 2004] 
Flavonoids are natural compounds that are highly abundant in all 
higher plants. They are of an immense chemical diversity and have 
been described to have a wide range of biological activities such as 
CNS-mediated activities. A clear anxiolytic effect of flavonoid 
glycosides with no signs of sedation could be observed in the EPM. 
[Fernandez SP et al, Viola H. et al] Since flavonoids have been 
used for generations and are found in our diet, it is unlikely that 
they would have side effects. [Campbell EL et al] 
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Fig. 4: Valerenic acid 
http://www.organische-chemie.ch/chemie/2007jun/valerensaeure.shtm 
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Fig. 5: Apigenin  
 
 
 
Fig. 6: Linarin  
http://www.chemblink.com/products/480-36-4.htm 
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5 Materials and Methods 
 
The compounds used in this study were diluted in a propylene 
glycol solution. In most studies, performed to prove the anxiolytic 
properties of VA in animal models the solutions were administered 
i.p. In this study, the solutions have been given orally since it is 
the most common way to administer Valerian drugs. 
 
5.1 Animal Models 
Animal models of anxiety examine the natural behavioral pattern of 
rodents in which animals are exposed to an aversive/threatening 
environment such as open, elevated arms of the EPM. [Garner M et 
al] An ideal animal model must fulfill three criteria: 
• Predictive validity: pharmacological treatments known to be 
effective in humans should induce comparable effects in 
animals 
• Face validity: the responses or symptoms observed in 
patients should be the same in the animal model 
• Construct validity: both humans and animal models should 
underlie the same basic principle 
Meeting all three criteria is difficult as there are many forms of 
pathological anxiety. Therefore, it is recommended to use more 
than one animal model to assess anxiolytic like properties of drugs. 
[Ohl F.] 
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In this thesis two animal models, the elevated plus maze test and 
the marble burying test, have been chosen to test anxiolytic like 
effects since both measure different parameters. The elevated plus 
maze is one of the most frequently used tests for unconditioned 
anxiety and its reliability has been proven in several studies. This 
test is based on the observation that rodents tend to avoid 
elevated and unprotected areas. [Ohl F] Another test performed in 
this study was the marble (defensive) burying test. Defensive 
burying can be observed in many rodents in response to an 
aversive stimulus. The marble burying test was developed to take 
advantage of this innate behavior to evaluate how many innocuous 
but novel glass marbles a rodent would bury. [Thomas A et al] 
Examining the response to previously harmless stimuli have been 
proven useful in modeling defensive behavior to fear extinction 
observed in patients with posttraumatic stress disorder (PTSD), 
specific and social phobias. [Garner M et al] 
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5.1.1 Elevated Plus Maze 
Anxiolytic activity was measured using the elevated plus maze test. 
The maze consisted of two open (31 cm x 5 cm x 1 cm) and two 
closed (31 cm x 5 cm x 15 cm) arms, extending from a central 
platform (5 cm x 5 cm) and elevated to a height of 40 cm above 
the floor [Fig 7]. On the wooden base frame, the closed arms were 
made of opaque plastic, while the open arms were made of the 
same material with a slight elevated edge. Mice were individually 
placed on the center of the maze facing a closed arm and the 
number of entries and the time spent in closed and open arms 
were recorded during a 6 minutes observation period. Arm entries 
were defined as entry of all four paws into an arm.  
The percentage of the time spent on open arms (100 x open/total 
time) was calculated for each animal. The EPM is claimed to be an 
ethologically valid animal model of anxiety because it uses natural 
stimuli that can induce anxiety in humans [Pellow S et al]. It is 
assumed that the open arms of the maze combine the fear of a 
novel, brightly-lit open space and the fear of balancing on a 
narrow, raised platform. The closed arms have high walls forming a 
narrow alley that offers good protection against predators. When a 
rat or mouse is allowed to explore the EPM freely, for a certain time 
(usually 6 minutes), it spends only 20-25% of the time exploring 
the open arms. The measures of anxiety are the number of open 
arm entries expressed as a percentage of the total number of arm 
entries and the amount of time spent on the open arms. In the 
potentially dangerous situation of the EPM, rodents display a range 
of behaviors that could be interpreted as the assessment of the 
potential risk. These include head dipping and stretch-attend 
postures. These actions can take place in the closed arms 
(protected) or on the open arms (unprotected). This behavior can 
be characterized by open arm avoidance with a consistent 
preference for the closed arms. The rank order preference profile is 
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closed > centre > open. Together with several other measures of 
hesitancy and inactivity, these behaviors are known as risk 
assessment behaviors [Bourin M et al]. Anxiolytic compounds 
appear to decrease risk assessment behaviors and increase 
unprotected activity. The simplicity of this test is considered one of 
the main advantages of the EPM. [Lister RG, 1987] 
 
Fig. 7: Elevated Plus Maze Apparatus  
http://www.infolizer.com/?title=Elevated+plus+maze 
 
Setting 
Two mazes were placed directly side by side so that a closed arm 
of one component adjoined to a closed arm of the other 
component. Tape was used to fix the construction. The floor lamps 
were placed between the open arms on each side of the maze. The 
lamps are directed towards the ceiling and not at the maze to 
reduce the formation of shades. During the experiment only the 
floor lamps are turned on while the ceiling lights are turned off. The 
video camera is fixed above the maze. The video camera is 
connected to the computer so if the camera is in the right position 
can be checked with the software “Directshow Encode”, which is 
used to record the whole experiment. 
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5.1.2 Marble-burying test 
 
Defensive burying is interpreted as unconditioned, species-specific 
response towards certain olfactory, tactile and visual stimuli, which 
will elicit avoidance behavior under appropriate conditions [Treit D 
et al]. This test consists of a plexiglas cage of 23 x 17 x 14 cm with 
a smooth lid punctured with small ventilation holes [Fig. 8]. The 
floor is covered with a 5 cm layer of sawdust and 25 glass marbles 
are placed in contact with each other in the center of the cage. 
Various studies about MBT also suggest placing the marbles in 
different ways [Bourin M et al]. The mouse is placed in the cage for 
30 minutes after which it will be removed and the burying response 
will be quantified by counting the number of marbles that are more 
than two thirds covered with sawdust. A diminution of the burying 
reflex reveals a positive anxiolytic-like effect. However, questions 
regarding the specificity of marble burying as an indicator of 
anxiety came up due to studies showing a decrease in marble 
burying after application of antipsychotic drugs. Several studies 
suggest the marble burying behavior is rather associated with 
digging behavior than with defensive burying and reflects a more 
obsessive-compulsive like behavior rather. Therefore, this test has 
been performed only. It was considered that it was difficult to 
interpret the results of this test given that marble burying may be 
simply a by-product of digging behavior.. [Bourin M, 2007, Treit D, 
1981].  
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Fig. 8 MBT – cage with aligned marbles 
http://www.cincinnatichildrens.org/research/cores/abc/marble.htm 
 
5.2 Animals 
Male BL6/C57J mice between 6-12 weeks old and weighing 18-30 g 
were purchased from Harlan (Indianapolis, IN, USA). Mice were 
housed in cages of 5 at 20 ± 1°C in a 12-h light/dark cycle. Tap 
water and standard food pellets were available ad libitum. Groups 
of 12 to 14 mice were randomly assigned to different treatment 
groups and tested in a varying order. Animals were tested 
repeatedly under the same experimental conditions. All 
experiments were carried out in a quiet room under controlled light 
conditions between 9:00 a.m. and 2:00 p.m. due to the reversed 
circadian rhythm and secretion of endogenous cortisol in rodents. 
All animals were housed and all experiments performed according 
to the policies and guidelines of the Institutional Animal Care and 
Use Committee (IACUC) of the University of Florida, Gainesville, 
U.S.A. 
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5.3 Drugs 
Diazepam ampoules (5 mg/ml Hoffmann-La Roche, Basel, 
Switzerland) were used as reference drugs. Deionized water 
(Millipore quality) containing 0.5% propylene glycol (Fisher 
Scientific, Inc; Fair Lawn, NJ, USA) was used as control solution. 
Diazepam was diluted to 1.5 mg in 10ml deionized water 
containing 0.5% propylene glycol. Four different concentrations 
(0.25, 0.5, 1, 2 mg/Kg body weight) of the valerenic acid (Institute 
of Pharmacognosy, University of Vienna) were prepared by in 10 ml 
deionized water with 0.5% propylene glycol to form a homogenous 
suspension.  
Flavonoids as linarin and apigenin were also tested (Indofine 
Chemical Company Inc., Hillsborough, NJ, USA. Three 
concentrations of each flavonoid (linarin; 2.5, 5, 10 mg/Kg and 
apigenin; 1, 3, 6 mg/Kg) were prepared in 10 ml of the 0.5% 
propylene glycol solution and put in the sonicator for 10 minutes. 
Apigenin and linarin were non-soluble in this solution, therefore the 
flavonoid samples were administered as a suspension. All solutions 
were prepared freshly on the respective test day and administered 
orally (p.o.) 60 minutes before testing by a feeding needle in a 
volume of 0.1 ml/10g body weight of mice. Previous data from our 
lab has shown that the drug application 60 minutes prior to the 
tests yields the most reliable and reproducible results with 
diazepam compared to 30 minutes or 2 hours [Grundmann O. et 
al]. 
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5.4 Data analysis 
The EPM test was videotaped using the high-resolution video 
camera WV-CP244 (Panasonic, Secaucus, NJ, USA). The 
computerized analysis of the videos was performed using TopScan, 
Top View Animal Behavior Analyzing System (version 1.00, Clever 
Sys Inc. Preston, VA, USA). 
 
Fig. 9: Computer analysis of the EPM - TopScan software, Picture shows the 
standard setup in our laboratory. Two mice are tested simultaneously. 
5.5 Statistics: 
Calculation of the percentage of time and number of entries on the 
open arms with 95% confidence limits and comparisons of the 
results were performed using GraphPad Prism (version 5.00, 
GraphPad Software Inc., San Diego, CA, USA). The statistical 
analysis of data was performed by one-way analysis of variance 
(ANOVA) followed by Student-Newman-Keul's multiple comparison 
test. In all cases differences were considered significant if p<0.05. 
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5.6 Experimental design 
 
Group Treatment N per group 
1 
Control (vehicle; 0.5% propylene glycol in 
deionized water, treatment oral) 
12 
2 Diazepam 1.5 mg/Kg 12 
3 Valerenic acid 0.25 mg/Kg 12 
4 Valerenic acid 0.5 mg/Kg 12 
5 Valerenic acid 1 mg/Kg 12 
6 Valerenic acid 2 mg/Kg 12 
 
Group 
Treatment N per group 
1 
Control (vehicle; 0.5% propylene glycol in 
deionized water, treatment oral) 
12 
2 Diazepam 1.5 mg/Kg 12 
3 Apigenin 1 mg/Kg 12 
4 Apigenin 3 mg/Kg 12 
5 Apigenin 6 mg/Kg 12 
 
Group 
Treatment N per group 
1 
Control (vehicle; 0.5% propylene glycol in 
deionized water, treatment oral) 
12 
2 Diazepam 1.5 mg/Kg 12 
3 Linarin 2.5 mg/Kg 12 
4 Linarin 5 mg/Kg 12 
5 Linarin 7.5 mg/Kg 12 
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5.7 Experimental Run 
 
The following flow chart shows the experimental run on one day. 
 
Bringing mice into the testing room – 
accomodation for 1 hour
Preparation of test solution – 
dissolving extracts in vehicle
1 hour after mice were brought to the testing 
room – startin feeding mice with test solution
1 hour after first 2 mice were fed, these 2 mice 
placed on EPM – starting recording
Evaluating the 
videos
 
Fig. 10: Experimental run 
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6 Results 
 
One-Way Analysis of Variance revealed that mice treated with 
valerenic acid at a dose of 0.5 mg/Kg tended to enter more 
frequently into the open arms. Additionally they spent more time 
outside the closed arms in comparison to the control group. The 
number of open arm entries decreases with each higher 
concentration indicating an inverted-U-shaped dose response 
curve. There were no significant differences neither in the number 
of open arm entries nor in the time spent on the open arms at the 
doses of 1 and 2 mg/Kg to the control group. The lower dose of 
0.25 mg/Kg had the lowest number of open arm entries and the 
least time spent on the open arms. There were no significant 
differences on the distance set back [Fig 11 - 13]. 
Diazepam showed a significant increase on open arm entries and 
on the time spent on the open arms versus the control group. 
Apigenin and linarin showed neither an increase of open arm 
entries nor on time spent on open arms compared to the control 
group [Fig. 14 - 19]. 
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Fig. 11: Number of open arm entries after VA application  
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Fig. 12: Percentage of time spent on OA after VA application 
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Fig 13: Distance in mm set back in 6 min after VA application 
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Fig. 14: Number of open arm entries after application of apigenin 
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Fig. 15: Percentage of time spent on OA after application of apigenin 
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Fig 16: Distance in mm set back in 6 min after application of apigenin 
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Fig. 17: Number of open arm entries after application of linarin 
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Fig. 18: Percentage of time spent on OA after application of linarin 
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Fig 19: Distance in mm set back in 6 min after application of linarin 
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7 Discussion and Conclusion 
 
Research of valerian is exclusively focused on its sedative and 
spasmolytic properties. Furthermore no single constituent has been 
shown to be responsible for valerian’s total action. Initially it was 
believed that the essential oil was the component responsible for 
the sedative effect of valerian but nowadays it is known that the 
essential oil is accounted for only one-third of the sedative activity 
of the extract. Valepotriates were also excluded as the active 
component. Therefore, in the present study we focused on other 
constituents which have already been proven [Khom et al] to have 
an effect on the central nervous system such as isolated 
compounds as valerenic acid and different flavonoids. Valerenic 
acid and acetylvalerenic acid have been reported to inhibit GABA 
transaminase which as a result prolongs the inhibitory effect of 
GABA [Am Herb Pharmac]. Benzodiazepines exert their actions via 
the GABA-ergic system. Valerian extracts contain amino acid GABA 
in insufficient quantity to account for the activity but GABA does 
not cross the intact blood-brain barrier. Valerenic acid has been 
proven to interact with the GABAA-receptor complex but 
independent to the BZD binding site. [Khom S, 2007] A few other 
studies focused on the anxiolytic effects of the flavonoids apigenin 
and linarin which can as well be found in valerian.  
Animals cannot model every aspect of human anxiety but studies in 
animals permit detailed investigations for neurobiological and 
psychological processes in states of fear. Due to divers 
mechanisms mediating anxiety there are different animal behavior 
models which are more appropriate to one type of anxiety. The 
manner in which animals react to threatening stimuli or situations 
distinguishes considerably to the human defensive behavior. There 
are basically two types of animal behavior models used to detect 
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the anxiolytic effect of drugs. Models can be based on conditioned 
or unconditioned behavior. Whilst models relying on conditioned 
behavior need specific trained animals, the model based on 
unconditioned behavior relies on natural behavioral reactions. 
Unconditioned models have a higher degree of validity and are 
easier to conduct given that animals need not to be trained. 
Potential threats that lead to unconditioned responses are amongst 
others social interaction, light/dark exploration or defensive 
burying. The elevated plus maze is an unconditioned model used to 
study anxiolytic effects of drugs for generalized anxiety disorders. 
This test permits a rapid screening of anxiety-modulating drugs 
without training or involvement of complex schedules. [Bourin M, 
et al] The elevated plus maze is considered to be an etiologically 
valid animal model of anxiety. An anxiolytic agent increases the 
frequency of entries into the open arms and increases the time 
spent on open arms of the EPM. [A.A. Roberts]. The validity of the 
marble burying test is controversial since it shows no selectivity for 
anxiolytics. An alteration on marble burying could be observed for 
anxiolytics but also for antipsychotics. Studies have been 
conducted to improve the predictive validity of the marble burying 
test; by measuring locomotor activity using a video tracking 
system or by using specific mouse strains. Some strains show more 
burying activity than others. It cannot be excluded that strain-
specific pharmacodynamic and/or pharmacokinetic properties 
influence behavior in MBT. [Nicolas LB et al] 
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In the present study different concentrations of the isolated 
compounds valerenic acid, apigenin and linarin were orally 
administered to mice. An anxiolytic effect could be observed for 
valerenic acid at the dose of 0.5 mg/kg since the frequency of the 
open arm entries was increased to the control group. An anxiolytic 
effect could be observed neither at a lower dose nor on higher 
doses. Interestingly the number of open arm entries decreases 
with increasing dose. It is assumed that an open channel block due 
to a higher dose of valerenic acid might be the reason. [S. Khom, 
et al.]. The flavonoids apigenin and linarin did not show an 
anxiolytic effect at any dose in the EPM. It is still uncertain which 
component of valerian induces the anxiolytic effect. Valerenic acid 
shows an anxiolytic effect, though studies suggest a possible 
synergism between multiple active compounds. A co-application of 
VA and linarin showed a potentiating effect [S. Khom, AA Roberts]. 
Therefore, further studies on synergism between valerian 
compounds could offer promising results. 
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9 Figure legend 
 
Fig. 1: GABAA receptor 
http://www.cnsforum.com/imagebank/section/Receptor_Gabanergic/default.aspx  
Fig. 2: Valeriana officinalis L. 
http://www.botanical.com/botanical/mgmh/v/valeri01-l.jpg 
Fig. 3: Valeriana officinalis L. 
http://www.botanikus.de/Heilpflanzen/Baldrian/baldrian.html 
Fig. 4: Valerenic acid 
http://www.organische-chemie.ch/chemie/2007jun/valerensaeure.shtm 
Fig. 5: Apigenin, drew with ChemSketch 
Fig. 6: Linarin  
http://www.chemblink.com/products/480-36-4.htm 
Fig. 7: Elevated Plus Maze Apparatus  
http://www.infolizer.com/?title=Elevated+plus+maze 
Fig. 8: MBT – cage with aligned marbles 
http://www.cincinnatichildrens.org/research/cores/abc/marble.htm 
Fig. 9: Screenshot of TopScan software, standard setup in our 
laboratory 
Fig. 10: Flow chart: experimental run made with MS Visio 
Fig. 11 – 19: Results: Graphs on the results exported from 
GraphPad Prism 5 
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